What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?Clémence Lacroix, Olivier Blin, Romain Guilhaumou et al.|Frontiers in Pharmacology|2022Cited by 16
Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance NetworkPauline Gandolfo, Joëlle Micallef, Louise Carton et al.|Fundamental and Clinical Pharmacology|2024Cited by 13
Monitoring misuse and abuse of psychoactive substances in France: Insights from substance abuse treatment facilities through the OPPIDUM programClémence Lacroix, Joëlle Micallef, Élisabeth Frauger et al.|Therapies|2024Cited by 11
Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022Clément Garnier, Joëlle Micallef, Thomas Soeiro et al.|CNS Drugs|2024Cited by 8
Augmentation de l’abus de méthylphénidate : repérage et profils sur 13 annéesClémence Guerra, Élisabeth Frauger, Joëlle Micallef et al.|Therapies|2022Cited by 7